They joined us.
Creation : 31/10/2023
Employees : 2
Address : Lyon
Activity (biotech/medtech/healthtech) : Biotech
Who ?
SIRIUS NEOSIGHT is an innovative company developing a breakthrough technology focused on a new membrane marker capable of universally and highly efficient discriminating and purifying Circulating Tumor Cells (CTCs) present in in liquid biopsies. The purification of these tumor cells makes it possible to consider their use in the detection of cancers at different stages of development as well as as a new predictive tool for resistance to treatments and the identification of personalized therapies for aggressive cancers with a high metastatic incidence that do not present no clearly defined therapeutic orientation in the care pathway.
Why joined us ?
Membership in Lyonbiopôle will allow SIRIUS NEOSIGHT to access a large network of entrepreneurs in the health field but also industrialists at the forefront of innovation and to participate in scientific events of interest allowing expand its network of partners. Lyonbiopole will also be a key partner in supporting the fundraising phases for the company.
Agnès BASTID – CEO
